Evidence map›Paper›PMID 41634873›Full record

ArticleActa neuropathologica communications2026

Chaperone mediated autophagy is deficient in spinal motoneurons of ALS patients with TDP-43 proteinopathy.

Daniel Garrigos, Marta Martinez-Morga, Ana Pombero, Raquel García-Lopez, Diego Pastor, Dolores Riquelme, Miguel Blanquer, Francisca Iniesta, Rut Valdor, Emilio Geijo-Barrientos and 3 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel GarrigosInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain.
Marta Martinez-MorgaInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain.
Ana PomberoInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain.
Raquel García-LopezInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain.
Diego PastorSports Research Centre, Department of Sport Sciences, Miguel Hernández University, Elche, Spain.
Dolores RiquelmeInstituto Murciano de Investigación Biosanitaria Pascual Parrilla (IMIB), Murcia University, Murcia, Spain.
Miguel BlanquerInstituto Murciano de Investigación Biosanitaria Pascual Parrilla (IMIB), Murcia University, Murcia, Spain.
Francisca IniestaUniversidad Católica de Murcia (UCAM), Murcia, Spain.
Rut ValdorInstituto Murciano de Investigación Biosanitaria Pascual Parrilla (IMIB), Murcia University, Murcia, Spain.
Emilio Geijo-BarrientosInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain.
Gunnar HargusInstitut für Neuropathologia. Universitätsklinikum Münster, München, Germany.
José María MoraledaInstituto Murciano de Investigación Biosanitaria Pascual Parrilla (IMIB), Murcia University, Murcia, Spain.
Salvador MartínezInstituto de Neurociencias (UMH-CSIC), San Juan de Alicante, Alicante, Spain. smartinez@umh.es.

Funding

Generalitat Valenciana (program Prometeo II) Grant Number 2018/041Instituto de Salud Carlos III (ISCIII) through the RICORS Project TERAV RD21/0017/0017; RD21/0017/0001Ministerio de Ciencia e Innovación Ramon y Cajal (RYC) 2019-027520-ISpanish Ministerio de Ciencia e Innovación SAF2017-83702-R and PID2020-11817RB-I00Spanish State Research Agency, through the "Severo Ochoa" Programme for Centres of Excellence in R&D Grant Numbers SEV-2017-0723
6 · The paper itself

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective loss of motor neurons (MNs), ultimately resulting in paralysis and respiratory failure within 3 to 5 years of onset. Fewer than 10% of ALS cases are familial (fALS), while the vast majority are sporadic (sALS) with an unknown etiology. A pathological hallmark of ALS is the accumulation of misfolded TDP-43 protein aggregates within MNs. Although TDP-43 is known to be degraded via chaperone-mediated autophagy (CMA), the status of CMA activity in sALS has not been previously explored. To investigate this, we analyzed CMA in human spinal cord tissue by assessing the expression of LAMP2A, a key lysosomal receptor and marker of CMA activity. In control samples, spinal cord MNs exhibited robust LAMP2A expression. In contrast, MNs from sALS patients showed a marked reduction in LAMP2A levels, coinciding with the presence of TDP-43 pathology. Notably, analysis of LC3, a marker of macroautophagy, revealed no significant differences in expression between control and sALS MNs. Interestingly, MNs within the Onuf’s nucleus, a population known to be resistant to degeneration in ALS, retained normal LAMP2A expression and did not exhibit TDP-43 aggregation in sALS cases. These findings demonstrated that CMA is essential for the clearance of TDP-43 in spinal cord MNs and that its dysfunction may contribute to the pathogenesis of sALS. Furthermore, the high dependence of spinal cord MNs on CMA activity may underlie their selective vulnerability to degeneration when CMA is impaired, and highlight CMA enhancement as a promising therapeutic strategy to restore proteostasis and prevent MN degeneration in ALS.

Indexed as

Amyotrophic Lateral SclerosisAutophagyChaperone-Mediated AutophagyMotor NeuronsSpinal CordTDP-43 ProteinopathiesAdultAgedDNA-Binding ProteinsFemaleHumansLysosomal-Associated Membrane Protein 2MaleMicrotubule-Associated ProteinsMiddle AgedDNA-Binding ProteinsLAMP2 protein, humanLysosomal-Associated Membrane Protein 2MAP1LC3A protein, humanMicrotubule-Associated ProteinsTARDBP protein, humanChaperone mediated autophagyDifferential vulnerability to neurodegenerationHuman motoneuronsMotor neurodegenerationsALS

Identifiers

PMID41634873
PMCPMC13014841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.